What happened
Shares of several top COVID-19 vaccine makers were sinking on Tuesday. Pfizer (NYSE: PFE) stock was down 2.7% as of 11:09 a.m. EDT. Shares of Pfizer's partner, BioNTech (NASDAQ: BNTX), were falling 7%. Moderna (NASDAQ: MRNA) stock was tumbling 5.4%. Novavax (NASDAQ: NVAX) was the biggest loser with its shares declining 8.1%.
So what
It's really not all that surprising that these stocks would give up much of the gains from Monday. FDA approval for the Pfizer-BioNTech vaccine was fully expected.
Now what
Pfizer, BioNTech, and Moderna hope to win EUAs for their vaccines in younger children within the next few months. The companies also will pursue full FDA approvals in these age groups. Novavax plans to file for EUA of its COVID-19 vaccine in the fourth quarter, with submissions in the U.K. and Europe coming even sooner.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
FDA Sees Covid Shots For Kids 'In The Coming Months,' But Stocks Stumble
Vaccine stocks dipped Friday after the FDA said it expects to authorize Covid shots for children "in the coming months."
U.S. administers 378.6 mln doses of COVID-19 vaccines - CDC
The United States has administered 378,569,717 doses of COVID-19 vaccines in the country as of Friday morning and distributed 454,332,805 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 377,622,065 vaccine doses the CDC said had gone into arms by Sept. 9 out of 452,781,195 doses delivered.
UPDATE 1- COVID-19 vaccines hold strong against Delta, protection waning in older adults
Three U.S. studies suggest COVID-19 vaccines offer strong protection against hospitalization and death, even in the face of the highly transmissible Delta variant, but vaccine protection appears to be waning among older populations, especially among those 75 and older. U.S.
FDA Says Strong Safety Data A Must For COVID-19 Vaccine Approval For Kids
The FDA said that clinical trials testing COVID-19 vaccines for children are expected to include a monitoring period of at least two months after half the participants get the shots to ensure safety. The comments come as vaccine makers race to submit clinical data seeking regulatory approval for vaccines in children below 12.
Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?
Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.
COVID-19 vaccines hold strong against Delta, protection waning in older adults
Three U.S. studies suggest COVID-19 vaccines offer strong protection against hospitalization and death, even in the face of the highly transmissible Delta variant, but vaccine protection appears to be waning among older populations, especially among those 75 and older. U.S.
UPDATE 1-U.S. FDA may authorize COVID-19 vaccine for kids based on two months of safety data
U.S. heath regulators said children in clinical trials testing COVID-19 vaccines should be monitored for at least two months for side effects, suggesting that the agency is considering a quicker path to authorize the shot for emergency use than full approval. The U.S.
Pfizer News & Analysis
Disclosure of Voting results of AGM (Regulation 44 (3) of SEBI (LODR) Regulations, 201..
About Pfizer
Pfizer Ltd., incorporated in the year 1950, is a Large Cap company (having a market cap of Rs 27,918.70 Crore) operating in Pharmaceuticals sector. Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Scrap for the year ending 31-Mar-2021.
Pfizer Share Price Update
Pfizer Ltd. share price moved down by -0.24 % from its previous close of Rs 6,102.75. Pfizer Ltd. stock last traded price is 6,088.00
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
